Pacira Value Chain Analysis
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Dive Deeper Into the Activities Behind the Analysis
This Pacira Value Chain Analysis helps you understand how Pacira creates value across support and primary activities in a clear, structured format. This page already includes a real preview of the analysis, so you can review the content before buying. Purchase the full version to get the complete ready-to-use report.
Support Activities
Firm Infrastructure
Pacira BioSciences, Inc. relies on a tight firm infrastructure because EXPAREL, ZILRETTA, and iovera work in regulated surgical and acute-care settings. Finance, legal, compliance, pharmacovigilance, and regulatory teams help protect FDA obligations and keep promotion aligned with label rules. That control matters because any gap can trigger warning letters, recalls, or sales disruption. In Pacira BioSciences, Inc., infrastructure is not overhead; it is part of product risk control.
Human Resource Management
Pacira BioSciences, Inc. needs skilled hires in manufacturing, clinical, regulatory, medical affairs, and hospital sales to support its non-opioid pain portfolio and sterile production. Strong retention keeps product education consistent, supports major-account coverage, and helps protect quality in a business with 2025 revenue of $??? and a small, specialized workforce. Even one gap in these roles can slow launches, delay hospital pull-through, and raise compliance risk.
Technology Development
Pacira BioSciences, Inc. builds its edge on EXPAREL's liposomal drug-delivery platform, so technology development matters more than scale alone. In fiscal 2025, R&D stayed tied to pipeline work, label expansion, clinical evidence, and manufacturing/process gains that help keep EXPAREL distinct from generic local anesthetics. That mix supports both new uses and margin defense.
Procurement
In fiscal 2025, Pacira BioSciences, Inc. procurement focused on active ingredients, lipids, packaging, sterile consumables, and outsourced services tied to drug production. This matters because any slip in supplier quality or lead times can delay batch release and limit hospital availability, while tighter sourcing helps protect gross margin. For a specialty pharma model like Pacira BioSciences, Inc., procurement is not just buying inputs; it is a control point for supply continuity, compliance, and cost discipline.
Pacira's 2025 support functions are now a compliance and supply-chain lever
Pacira BioSciences, Inc.'s support activities are built around 3 products, so firm infrastructure, talent, R&D, and sourcing all act as control points. In fiscal 2025, that matters most for FDA compliance, sterile supply, and label-backed growth for EXPAREL, ZILRETTA, and iovera.
| Support activity | 2025 focus |
|---|---|
| Infrastructure | Compliance, legal, pharmacovigilance |
| HR | Specialist retention |
| R&D | Label and process gains |
| Procurement | Sterile inputs and packaging |
What is included in the product
Detailed Word Document
Editable Excel File
Primary Activities
Inbound Logistics
Pacira BioSciences, Inc. runs inbound logistics through qualified sourcing of raw materials, APIs, lipids, and packaging parts, with tight vendor control and lot traceability. That matters in sterile injectables, where clean inputs and exact specs drive batch release and supply continuity.
In fiscal 2025, Pacira BioSciences, Inc. kept this flow tied to GMP controls and supplier qualification, which helps reduce contamination risk and shortages. One weak lot can stop a sterile run, so inbound quality is a direct cost and output issue.
Operations
Pacira BioSciences, Inc. turns specialized inputs into commercial supply through formulation, filling, testing, packaging, and release. This is the core making step for its 2 main brands, EXPAREL and ZILRETTA, which are prepared for hospitals and surgical centers. Operations matter because each batch must pass strict quality checks before release, so output is tied to both scale and compliance.
Outbound Logistics
Pacira BioSciences, Inc. uses controlled outbound logistics to move product through wholesalers, hospitals, and ambulatory surgery centers, so the right dose is available at the point of surgery. This matters because ambulatory surgery centers now perform about 60% of U.S. outpatient procedures, raising the need for tight delivery timing. Careful shipment planning and inventory control reduce stockouts and support time-sensitive acute-care use.
Marketing and Sales
Pacira BioSciences, Inc. uses a high-touch, account-based sales model that targets surgeons, anesthesiologists, pharmacists, and hospital leaders, so reps can address both clinical use and contract hurdles. The pitch is simple: non-opioid pain control, better postsurgical recovery, and EXPAREL's 72-hour release profile, which matters in value-focused care settings. In fiscal 2025, this direct approach helped keep EXPAREL centered on operating-room adoption and hospital formulary access.
Service
Pacira BioSciences, Inc. extends value after sale with medical information, reimbursement support, field education, and safety monitoring. In fiscal 2025, these services help hospitals use Pacira BioSciences, Inc. products correctly, reduce coverage friction, and support repeat use across procedure sites. That service layer turns a one-time sale into longer customer retention and smoother adoption.
Pacira's 2025 Focus: GMP Manufacturing, Controlled Delivery, and Clinical Support
Pacira BioSciences, Inc. primary activities in fiscal 2025 centered on sterile making, testing, and release of EXPAREL and ZILRETTA, with each batch cleared only after GMP quality checks. Distribution stayed tightly controlled through hospitals, wholesalers, and ambulatory surgery centers, where timing matters for surgery use. Sales were account-based, and post-sale support covered reimbursement, education, and safety monitoring.
| Primary activity | Fiscal 2025 focus |
|---|---|
| Operations | Formulation, fill, test, release |
| Outbound logistics | Hospital and ASC delivery |
| Marketing and sales | Account-based clinical selling |
| Service | Reimbursement and education |
What You See Is What You Get
Pacira Reference Sources
This is the actual Pacira Value Chain Analysis document you'll receive upon purchase – no surprises, just the full professional file. The preview below is taken directly from the complete report, so what you see is what you get. After checkout, you'll unlock the full, detailed version ready to use.
Frequently Asked Questions
Pacira BioSciences, Inc.'s value chain is anchored by proprietary drug-delivery science and a focused non-opioid portfolio. EXPAREL is designed for postsurgical pain relief for up to 72 hours, while ZILRETTA and iovera° give the company 3 commercial platforms across injectable and device-based pain care. That mix gives Pacira BioSciences, Inc. more than one commercial path to surgeon and hospital demand.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.